相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Metastatic Renal Cell Carcinoma Presenting as a Rapidly Enlarging Endotracheal Mass Due to Hyperprogression on Anti-PD1 Immunotherapy
Steven G. Hoshal et al.
ENT-EAR NOSE & THROAT JOURNAL (2021)
Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma
M. Schuiveling et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
Catherine L. Tan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
Jiali Yu et al.
NATURE MEDICINE (2021)
Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy
Christopher Tay et al.
CANCERS (2021)
Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation
Wan Du et al.
CANCER DISCOVERY (2021)
LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy
Gaopeng Li et al.
NATURE CELL BIOLOGY (2021)
Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Hyo Jung Park et al.
JAMA NETWORK OPEN (2021)
Hyperprogression after nivolumab for melanoma: A case report
Mesut Yilmaz et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2020)
Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study
Roberto Petrioli et al.
ANTI-CANCER DRUGS (2020)
FDG PET Findings of Hyperprogression During Immunotherapy in a Patient With Hepatocellular Carcinoma
Jingnan Wang et al.
CLINICAL NUCLEAR MEDICINE (2020)
Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1
Yu Peng et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
Andrea Forschner et al.
CANCERS (2020)
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Jing Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling
Snahlata Singh et al.
NATURE CELL BIOLOGY (2020)
Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm
Caroline Robert et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
PAK4 inhibition improves PD-1 blockade immunotherapy
Gabriel Abril-Rodriguez et al.
NATURE CANCER (2020)
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Giuseppe Lo Russo et al.
CLINICAL CANCER RESEARCH (2019)
BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade
Neda Nikbakht et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report
Ilke Tunali et al.
LUNG CANCER (2019)
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
C. G. Kim et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
Weimin Wang et al.
NATURE (2019)
Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
Zhi Ji et al.
BMC CANCER (2019)
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor
Youjin Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Anna M. Paczulla et al.
NATURE (2019)
Clonal replacement of tumor-specific T cells following PD-1 blockade
Kathryn E. Yost et al.
NATURE MEDICINE (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer
Joaquim Bosch-Barrera et al.
ANTI-CANCER DRUGS (2019)
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Francisco Sanchez-Vega et al.
CELL (2018)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression (vol 128, pg 805, 2018)
Heng Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Flavia Castro et al.
FRONTIERS IN IMMUNOLOGY (2018)
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara et al.
JAMA ONCOLOGY (2018)
Impact of oncogenic pathways on evasion of antitumour immune responses
Stefani Spranger et al.
NATURE REVIEWS CANCER (2018)
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Stephane Champiat et al.
CLINICAL CANCER RESEARCH (2017)
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade
Tavi Nathanson et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Integrative clinical genomics of metastatic cancer
Dan R. Robinson et al.
NATURE (2017)
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Robert T. Manguso et al.
NATURE (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
E. Saada-Bouzid et al.
ANNALS OF ONCOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
The Warburg Effect: How Does it Benefit Cancer Cells?
Maria V. Liberti et al.
TRENDS IN BIOCHEMICAL SCIENCES (2016)
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Randy F. Sweis et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
Blanca Homet Moreno et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma
Naoki Oshimori et al.
CELL (2015)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
NAD+ and sirtuins in aging and disease
Shin-ichiro Imai et al.
TRENDS IN CELL BIOLOGY (2014)
ARF and p53 Coordinate Tumor Suppression of an Oncogenic IFN-β-STAT1-ISG15 Signaling Axis
Jason T. Forys et al.
CELL REPORTS (2014)
SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating β-catenin
Petra Simic et al.
EMBO MOLECULAR MEDICINE (2013)
Small-Molecule Inhibitors of Acetyltransferase p300 Identified by High-Throughput Screening Are Potent Anticancer Agents
Heng Yang et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Glucose-Induced β-Catenin Acetylation Enhances Wnt Signaling in Cancer
Ana Chocarro-Calvo et al.
MOLECULAR CELL (2013)
Wnt/β-Catenin Signaling and Disease
Hans Clevers et al.
CELL (2012)
A restricted cell population propagates glioblastoma growth after chemotherapy
Jian Chen et al.
NATURE (2012)
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis
Dimitrios Anastasiou et al.
NATURE CHEMICAL BIOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation
Weiwei Yang et al.
NATURE (2011)
Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses
Dimitrios Anastasiou et al.
SCIENCE (2011)
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271
Alexander D. Boiko et al.
NATURE (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
Bryan T. MacDonald et al.
DEVELOPMENTAL CELL (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect
E. Lara et al.
ONCOGENE (2009)
Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth
Taro Hitosugi et al.
SCIENCE SIGNALING (2009)
Epidermal growth factor receptor (EGFR) signaling in cancer
N Normanno et al.
GENE (2006)
Immunosuppressive networks in the tumour environment and their therapeutic relevance
WP Zou
NATURE REVIEWS CANCER (2005)
Why do cancers have high aerobic glycolysis?
RA Gatenby et al.
NATURE REVIEWS CANCER (2004)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Acetylation of β-catenin by CREB-binding protein (CBP)
D Wolf et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
分享论文
